Correlation between concentrations of NAMPT and NMNAT1 and the risk of upper respiratory infections in the island reef

Table 1 Clinical symptoms and severity of illness (pneumonia severity index score)

Pathogenic microorganisms	Clinical symptoms and severity of illness (PSI score)
	Low risk (≤ 90 points)	Medium risk (91-130 points)	High risk (> 130 points)
Influenza H1N1 virus	10	4	1
Influenza B virus	10	2	0
Streptococcus pneumoniae	1	3	1
Adenovirus	37	8	4
SARS-CoV-2	9	2	1

PSI: Pneumonia severity index; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Table 2 Comparison of nicotinamide phosphoribosyltransferase and nicotinamide nucleotide adenylyltransferase 1 concentrations among different pneumonia severity index scores, n (%)

	PSI classification
	Low risk	Medium risk	High risk
NAMPT (pg/mL) (IQR)	35.29 (34.68)2,3	27.22 (26.23)1,3	21.19 (21.71)1,2
NMNAT1 (pg/mL) (IQR)	42.49 (44.50)2,3	26.19 (26.52)1,3	18.24 (18.77)1,2

¹Indicates statistical significance when compared with the low-risk group.

²Indicates statistical significance when compared with the medium-risk group.

³Indicates statistical significance when compared with the high-risk group.

PSI: Pneumonia severity index; IQR: Interquartile range; NAMPT: Nicotinamide phosphoribosyltransferase; NMNAT1: Nicotinamide nucleotide adenylyltransferase 1.

Table 3 Comparison of concentrations of nicotinamide phosphoribosyltransferase and nicotinamide nucleotide adenylyltransferase 1 in low-risk patients with five common pathogenic microorganisms, n (%)

	Influenza H1N1 virus	Low risk (≤ 90 points)			SARS-CoV-2
		Influenza B virus	Streptococcus pneumoniae	Adenovirus
NAMPT (pg/mL) (IQR)	35.33 (35.41)	36.42 (36.43)	35.44 (35.45)	36.17 (38.19)	34.31 (34.39)
NMNAT1 (pg/mL) (IQR)	43.21 (42.95)	45.42 (45.09)	43.15 (42.35)	44.26 (44.41)	42.33 (41.91)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; NAMPT: Nicotinamide phosphoribosyltransferase; NMNAT1: Nicotinamide nucleotide adenylyltransferase 1; IQR: Interquartile range.

Table 4 Comparison of nicotinamide phosphoribosyltransferase and nicotinamide nucleotide adenylyltransferase 1 concentrations in medium-risk patients with five common pathogenic microorganisms, n (%)

	Influenza H1N1 virus	PSI (scores 91-130)			SARS-CoV-2
		Influenza B virus	Streptococcus pneumoniae	Adenovirus
NAMPT (pg/mL) (IQR)	27.32 (26.53)	27.4 (27.90)	25.31 (25.02)	26.29 (25.27)	26.19 (25.82)
NMNAT1 (pg/mL) (IQR)	27.22 (27.21)	26.4 (26.52)	25.19 (24.77)	26.49 (26.13)	25.22 (23.97)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; NAMPT: Nicotinamide phosphoribosyltransferase; NMNAT1: Nicotinamide nucleotide adenylyltransferase 1; IQR: Interquartile range; PSI: Pneumonia severity index.

Table 5 Comparison of nicotinamide phosphoribosyltransferase and nicotinamide nucleotide adenylyltransferase 1 concentrations in high-risk patients with five common pathogenic microorganisms, n (%)

	Influenza H1N1 virus	PSI (scores > 130)			SARS-CoV-2
		Influenza B virus	Streptococcus pneumoniae	Adenovirus
NAMPT (pg/mL) (IQR)	21.32 (19.66)	22.42 (21.56)	20.31 (18.91)	23.29 (21.92)	23.19 (22.25)
NMNAT1 (pg/mL) (IQR)	18.22 (19.10)	19.46 (20.08)	15.19 (17.79)	20.49 (18.62)	20.22 (20.54)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; NAMPT: Nicotinamide phosphoribosyltransferase; NMNAT1: Nicotinamide nucleotide adenylyltransferase 1; IQR: Interquartile range; PSI: Pneumonia severity index.